FDA keeps clin­i­cal hold in place on Lari­mar's lead drug with job cuts like­ly on the hori­zon

The FDA will ex­tend its clin­i­cal hold on Lari­mar Ther­a­peu­tics’ lead rare dis­ease drug CTI-1601, ask­ing for more da­ta be­fore it will re­con­sid­er the com­pa­ny’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.